[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Air Liquide Healthcare Spain\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645172","effectiveness-and-efficiency-of-home-telemonitoring-and-non-invasive-ventilation-in-patients-with-copd-and-hypercapnia-evaleco-100645172",false,"NCT07679646","Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)","Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia","EVALECO","Inclusion Criteria:\n\n1. Age between 50 and 90 years.\n2. Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to current Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, demonstrating non-fully reversible airflow limitation with a Forced Expiratory Volume in 1 second (FEV1) \\\u003C 50% of the predicted value confirmed by spirometry.\n3. Persistent hypercapnia, defined as PaCO2 \\> 53 mmHg documented for at least two weeks following an acute COPD exacerbation.\n4. History of two or more acute COPD exacerbations within the preceding year.\n5. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Prior ongoing treatment with home non-invasive ventilation (NIV) or Continuous Positive Airway Pressure (CPAP).\n2. Severe obstructive sleep apnea (OSA), defined as an Apnea-Hypopnea Index (AHI) \\>= 30.\n3. Inability of the patient or the primary caregiver to comprehend or operate the telemonitoring and NIV procedures.\n4. Estimated life expectancy of less than one year.\n5. Terminal heart failure (New York Heart Association \\[NYHA\\] Class III-IV) or unstable angina.\n6. Advanced renal insufficiency (creatinine clearance \\\u003C 30%) or inclusion in an active dialysis program.\n7. Hepatic cirrhosis or active inclusion in a liver transplant program.\n8. Severe psychiatric illness requiring antipsychotic medication, active ongoing treatment for substance or alcohol addiction, or lack of a fixed home address upon hospital discharge.\n9. Receipt of home palliative care.\n10. Institutionalization.\n11. Classification by the attending physician as non-compliant with medical therapies, treatments, or study protocols","ALL","50 Years","90 Years",{"count":21,"type":22},92,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive Pulmonary Disease (COPD) and persistent hypercapnia. In standard practice, patients with severe COPD and high carbon dioxide levels in their blood are treated with home non-invasive ventilation to support their breathing. This study compares two different care strategies over a one-year follow-up period:\n\n1. One group of patients will receive standard home non-invasive ventilation alone.\n2. Another group will receive home non-invasive ventilation combined with an automated telemonitoring system that tracks device parameters daily (such as air leaks, device usage, and breathing rates) and sends automated alerts to the healthcare team if deviations occur. The main goal of the project is to determine if adding a telemonitoring follow-up system can prevent clinical worsenings and significantly reduce the total number of days patients spend hospitalized due to severe COPD flare-ups. Additionally, the study will analyze the impact of both strategies on patients' overall health-related quality of life and the economic costs within the healthcare system.",[26,27],"Pulmonary Disease, Chronic Obstructive (COPD)","Hypercapnia",[29,30,31],"Home Noninvasive Ventilation","Telemonitoring","Respiratory Insufficiency","NOT_YET_RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":22},"2026-07",{"date":40,"type":22},"2026-12",{"name":42,"class":43},"Air Liquide Healthcare Spain","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":44},"100630847","home-ahcl-home-based-implementation-of-an-advanced-hybrid-closed-loop-system-with-telemonitoring-in-type-1-diabetes-100630847","NCT07492992","HOME-AHCL: Home-Based Implementation of an Advanced Hybrid Closed-Loop System With Telemonitoring in Type 1 Diabetes","Safety, Effectiveness, Quality of Life, Costs, and Efficiency of the Home Setup of the Hybrid Closed-Loop System in People With Type 1 Diabetes: Application of a Value-Based Diabetes Management Model","HOME-AHCL","Inclusion Criteria:\n\n* Diagnosis of type 1 diabetes.\n* Aged 18 years or older.\n* Candidate to initiate an Advanced Hybrid Closed-Loop (AHCL) system based on standard clinical criteria.\n* Access to the internet and\u002For a compatible smartphone to connect to the system.\n* Willingness to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Currently participating in another diabetes-related clinical trial.\n* Pregnant or planning to become pregnant during the study.\n* Inability to use the system autonomously (e.g., severe cognitive impairment or severe psychiatric disorders without support).\n* Medical contraindication for the use of insulin pumps or continuous glucose monitors (CGM).","18 Years",{"count":55,"type":22},80,"The goal of this observational study is to evaluate a new home-based setup and care model for an advanced hybrid closed-loop insulin pump system (Tandem with Control-IQ). The study will look at the safety, effectiveness, costs, and impact on quality of life in adults with type 1 diabetes.\n\nThe main questions it aims to answer are:\n\n* Is it safe for participants to start using the insulin pump system at home instead of the hospital? (Measured by the amount of time blood sugar is very low, under 54 mg\u002FdL).\n* Does this home-based care model help participants keep their blood sugar in a healthy range?\n* How does this model affect the participants' quality of life, device satisfaction, and overall experience?\n* Does this model reduce healthcare costs and the need for hospital visits?\n\nParticipants will:\n\n* Complete an online technical training course before the setup.\n* Receive a home visit from a specialized nurse to configure and start the insulin pump system.\n* Have their device data monitored remotely every 14 days by the nursing team to manage any health alerts.\n* Attend scheduled clinical follow-up visits at 1, 3, 6, and 12 months.\n* Answer surveys about their quality of life, their experience with the healthcare service, and their satisfaction with the new device.",[58],"Diabetes Mellitus Type 1",[60,61,62,63,30,64,65,66,67,68],"Type 1 Diabetes","Advanced Hybrid Closed Loop","Insulin Pump","Continuous Glucose Monitoring","Remote Patient Monitoring","Value-Based Healthcare","Home Care Services","Quality of Life","Cost-Effectiveness","2026-04-07",{"date":71,"type":36},"2026-04-13",{"date":73,"type":22},"2026-04",{"date":75,"type":22},"2028-04",{"name":42,"class":43},""]